STOCK TITAN
  1. Home
  2. Sec-filings
  3. FLGT
  4. [Form 4] Fulgent Genetics, Inc. Insider Trading Activity

FLGT President & COO Form 4 sale of 681 Fulgent Genetics shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. reported an insider transaction by its President and COO on a Form 4. On 11/24/2025, the officer sold 681 shares of common stock at a weighted-average price of $30.473. The filing explains that the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.

After this transaction, the officer beneficially owned 339,087 shares of Fulgent Genetics common stock directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The trust holdings are attributed because the officer serves on its investment committee, while disclaiming beneficial interest except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Xie Jian
Role President and COO
Sold 681 shs ($21K)
Type Security Shares Price Value
Sale Common Stock 681 $30.473 $21K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 339,087 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)
Footnotes (1)
  1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Xie Jian
(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE
(Street)
EL MONTE CA 91731
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/24/2025 S 681(1) D $30.473(2) 339,087 D
Common Stock 220,816 I By Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
2. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
/s/ Paul Kim as Attorney-in-Fact 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Fulgent Genetics (FLGT) report in this Form 4?

Fulgent Genetics reported that its President and COO sold 681 shares of common stock on 11/24/2025 in an open market transaction.

At what price were the Fulgent Genetics (FLGT) shares sold in the Form 4 filing?

The 681 shares of Fulgent Genetics common stock were sold at a weighted-average price of $30.473, based on trades between $30.33 and $30.62.

Why did the Fulgent Genetics (FLGT) officer sell 681 shares?

The filing states the shares were sold to satisfy tax withholding obligations that arose when certain restricted stock units vested.

How many Fulgent Genetics (FLGT) shares does the officer own after this transaction?

Following the sale, the officer beneficially owned 339,087 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust.

What is the officer’s relationship to Fulgent Genetics (FLGT)?

The reporting person is an officer of Fulgent Genetics, serving as President and COO, according to the Form 4.

How is the trust ownership of Fulgent Genetics (FLGT) shares described?

The 220,816 shares are held by The Hsieh Family Dynasty Trust. The officer serves on its investment committee and disclaims beneficial interest except for any pecuniary interest.